Last reviewed · How we verify
Osteomalacia
At a glance
| Generic name | Osteomalacia |
|---|---|
| Sponsor | National Institute of Dental and Craniofacial Research (NIDCR) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and (Phase 2)
- A Phase 2 Study of Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia (Phase 2)
- Head-to-head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-induced Osteomalacia (Phase 1)
- 68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia (Phase 1)
- Study of Calcium-phosphate Complications Induced by the Administration of IV Iron Supplementation in Patients With Rendu-Osler Disease (N/A)
- Serum Sclerostin Level in Patients With Vitamin D Deficiency (N/A)
- Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia (N/A)
- Effects Of Vitamin D Replacement Therapy on Serum FGF-23 Concentrations in Vitamin D Deficient Women In Short Term (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Osteomalacia CI brief — competitive landscape report
- Osteomalacia updates RSS · CI watch RSS
- National Institute of Dental and Craniofacial Research (NIDCR) portfolio CI